WallStSmart
DAWN

Day One Biopharmaceuticals Inc

NASDAQ: DAWN · HEALTHCARE · BIOTECHNOLOGY

$21.53
+0.00% today

Updated 2026-04-23

Market cap
$2.22B
P/E ratio
P/S ratio
14.06x
EPS (TTM)
$-1.04
Dividend yield
52W range
$6 – $22
Volume
4.5M

Day One Biopharmaceuticals Inc (DAWN) Financial statements

SEC filings — annual and quarterly data.

Income statement — annual

Item2019202020212022202320242025
Revenue$0.00$0.00$0.00$0.00$0.00$131.16M$158.18M
Revenue growth (YoY)+20.6%
Cost of revenue$155000.00$199000.00$531000.00$383000.00$5.28M$17.21M
Gross profit$-155000.00$-199000.00$-531000.00$-383000.00$125.88M$140.97M
Gross margin96.0%89.1%
R&D$13.90M$9.10M$43.58M$85.62M$130.52M$227.70M$148.13M
SG&A$1.01M$4.68M$29.16M$61.29M$75.54M$31.55M$120.59M
Operating income$-14.90M$-13.78M$-72.74M$-146.91M$-206.06M$-217.27M$-127.75M
Operating margin-165.7%-80.8%
EBITDA$-2000.00$-43.66M$-72.54M$-146.38M$-188.53M$-86.32M$-105.82M
EBITDA margin-65.8%-66.9%
EBIT$-14.91M$-43.81M$-72.74M$-146.91M$-188.92M$-88.35M$-109.30M
Interest expense$2.08M$30000.00$4000.00$4.75M
Income tax
Effective tax rate0.0%0.0%0.0%0.0%0.0%0.0%0.0%
Net income$-12.63M$-40.51M$-70.44M$-132.18M$-188.92M$-95.50M$-107.32M
Net income growth (YoY)-220.6%-73.9%-87.6%-42.9%+49.5%-12.4%
Profit margin-72.8%-67.8%

Frequently asked questions

What is Day One Biopharmaceuticals Inc's revenue?

Day One Biopharmaceuticals Inc's trailing twelve-month revenue is $158.18M. Revenue is the top line the whole model builds on, and at this scale the question shifts from how fast it grows to whether margins hold as it compounds.

How profitable is DAWN?

In its most recent fiscal year, DAWN ran a gross margin of 89.12%, an operating margin of -80.76%, and a net margin of -67.85%. Margins this high mean most of each extra dollar of revenue drops through to profit, which is the signature of real pricing power.

How much free cash flow does DAWN generate?

DAWN produced $-104.08M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.